New drug duo aims to shrink head and neck tumors
Disease control
Recruiting now
This study tests whether adding ficerafusp alfa to standard immunotherapy (pembrolizumab) can shrink tumors or extend life in people with advanced head and neck cancer that has spread or come back. About 650 adults with PD-L1-positive cancer will receive either the combination or…
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC